Cover About Us / About the cover Financial Highlights To Our Shareholders Operational Effectiveness Volunteerism: Thriving at BD     Battle Against HIV/AIDS     Giving to Children with Cancer     Battling Diabetes     Community Service Awards A Passion for Caring     New Frontiers     Making Motivation Easier     Curing Infection     Two Generations of Caring Enterprise Profile     BD Medical     BD Diagnostics     BD Biosciences Financials     Financial Review     Financial Statements     Notes to Consolidated Financial Statements Quarterly Data (unaudited) Corporate Information Board of Directors Corporate Officers Back Cover

Quarterly Data (unaudited) Thousands of dollars, except per-share amounts   2005     1st (B)    2nd (B)    3rd (B)    4th (B)    Year (B)  Revenues $ 1,288,369   $ 1,365,530   $ 1,381,306   $ 1,379,476   $ 5,414,681   Gross Profit   653,868     687,512     694,542     716,730     2,752,652   Income from Continuing Operations   194,398     186,509     189,801     121,575     692,283 (C)  Earnings Per Share:    Income from Continuing Operations   .77     .74     .75     .49     2.75      Income from Discontinued Operations   —     .01     —     .11     .12      Basic Earnings Per Share   .78     .74     .75     .60     2.87      Income from Continuing Operations(A)   .74     .71     .73     .47     2.66      Income from Discontinued Operations(A)   —     .01     —     .11     .11      Diluted Earnings Per Share(A)   .75     .72     .73     .58     2.77     2004     1st     2nd     3rd     4th     Year   Revenues $ 1,185,120   $ 1,253,633   $ 1,242,714   $ 1,253,278   $ 4,934,745   Gross Profit   550,865     624,117     627,101     632,300     2,434,383 (D)  Income from Continuing Operations   124,925     164,083     110,162     183,334     582,504 (D)(E)  Earnings Per Share:    Income from Continuing Operations   .49     .65     .43     .73     2.30      Loss from Discontinued Operations   —     —     —     (.46 )    (.46 )     Basic Earnings Per Share   .50     .65     .43     .27     1.85      Income from Continuing Operations(A)   .48     .62     .42     .70     2.21      Loss from Discontinued Operations   —     —     —     (.44 )    (.44 )     Diluted Earnings Per Share   .48     .62     .41     .26     1.77   (A)    Total per share amounts may not add due to rounding. (B)    Includes the impact of share-based compensation expense, as discussed further in Note 2. (C)    Includes the tax charge of $77,200 in the fourth quarter related to the planned repatriation of foreign earnings in 2006 under the American Jobs Creation Act of 2004, as discussed in Note 6. (D)    Includes the $45,024 charge in the first quarter related to blood glucose monitoring (BGM) products, as discussed in Note 19. (E)    Includes the litigation settlement of $100,000 in the third quarter, as discussed in Note 16.